WJPR Citation New

  All Since 2019
 Citation  7475  4312
 h-index  28  21
 i10-index  197  83

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

EVALUATION OF PARISHEKA-BASTI & VIRECHANA WITH NAVKARSHIK KWATH IN VATARAKTA W.S.R. TO SCLERODERMA

Harishma*, Piyush Gupta and Shivani Mahajan

.

Abstract

The prototypic autoimmune diseases involving skin typically result in epithelial injury and autoantibodies to characteristic cellular antigens. Disease-specific autoantibodies are also found in scleroderma and scleroderma is different from other cutaneous autoimmune diseases. Multiple factors and combinations of factors (Immune system, vascular and extracellular matrix abnormalities) are the most likely triggers in an individual with a genetic predisposition to scleroderma. These lead to increased synthesis of normal collagen in skin, lungs and gut in the systemic form of scleroderma (Systemic sclerosis). Scleroderma or Systemic Sclerosis of contemporary medical science by its similarity in symptoms and aetiological factors can be correlated with “Vatarakta”. In Ayurveda three basic treatment principles are mentioned- Shodhana, Shamana, Nidan parivarjan. Basti is the prime treatment modality of Ayurveda and according to Acharya Charka there is no treatment of Vatarakta efficient as Basti. Hapushadi Yapana Basti is specially described for management of Sarvang Vatarakta. Hapushadi Yapana Basti and Guduchiyadi Tail administered as per Yog Basti and Parisheka with Dashmool kwath with Godhan Arka. After the completion of course of treatment all the patients were prescribed with Navkarshik kwath. In another group we employed Virechana which is mentioned in Vatashonita chikitsa. Assessment was done on subjective and objective parameters and obtained data was analysed using appropriated statistical tests and conclusion was drawn that the therapy of is highly significant in cases of Vatarakta. In Subjective Parameters, In Group A 20% of the patients were showed moderate improvement and mild improvement in 50% patients. Group B provided marked improvement in 30% of the patients, moderate improvement in 40% patients, mild improvement in 30%.

Keywords: Vatarakta, scleroderma, Hapushadi Yapana Basti, Virechana, Navkarshik Mahakashaya.


[Full Text Article]  [Download Certificate]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More